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Background: Known genetic variants can account for 10% to 20% of all cases with autism spectrum disorders
(ASD). Overlapping cellular pathomechanisms common to neurons of the central nervous system (CNS) and in
tissues of peripheral organs, such as immune dysregulation, oxidative stress and dysfunctions in mitochondrial and
protein synthesis metabolism, were suggested to support the wide spectrum of ASD on unifying disease
phenotype. Here, we studied in patient-derived lymphoblastoid cell lines (LCLs) how an ASD-specific mutation in
ribosomal protein RPL10 (RPL10[H213Q]) generates a distinct protein signature. We compared the RPL10[H213Q]
expression pattern to expression patterns derived from unrelated ASD patients without RPL10[H213Q] mutation. In
addition, a yeast rpl10 deficiency model served in a proof-of-principle study to test for alterations in protein patterns
in response to oxidative stress.
Methods: Protein extracts of LCLs from patients, relatives and controls, as well as diploid yeast cells hemizygous for
rpl10, were subjected to two-dimensional gel electrophoresis and differentially regulated spots were identified by
mass spectrometry. Subsequently, Gene Ontology database (GO)-term enrichment and network analysis was
performed to map the identified proteins into cellular pathways.
Results: The protein signature generated by RPL10[H213Q] is a functionally related subset of the ASD-specific
protein signature, sharing redox-sensitive elements in energy-, protein- and redox-metabolism. In yeast, rpl10
deficiency generates a specific protein signature, harboring components of pathways identified in both the RPL10
[H213Q] subjects’ and the ASD patients’ set. Importantly, the rpl10 deficiency signature is a subset of the signature
resulting from response of wild-type yeast to oxidative stress.
Conclusions: Redox-sensitive protein signatures mapping into cellular pathways with pathophysiology in ASD have
been identified in both LCLs carrying the ASD-specific mutation RPL10[H213Q] and LCLs from ASD patients without
this mutation. At pathway levels, this redox-sensitive protein signature has also been identified in a yeast rpl10
deficiency and an oxidative stress model. These observations point to a common molecular pathomechanism in
ASD, characterized in our study by dysregulation of redox balance. Importantly, this can be triggered by the known
ASD-RPL10[H213Q] mutation or by yet unknown mutations of the ASD cohort that act upstream of RPL10 in
differential expression of redox-sensitive proteins.
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More than 1% of the general population display ASDs
(autism spectrum disorders) which encompass early
childhood autism, Asperger-Syndrome and pervasive-
developmental-disorders not-otherwise-specified [1]. ASD
patients are characterized by a clinically assessed triad of
symptoms of impairments in reciprocal social interaction
and communication, and of restricted interests and/or re-
petitive behaviors [2]. The heritability of ASD is estimated
to range between 37% to 80% for the disorder [3-5] de-
pending on sample size and structure of the studies. Gen-
etic studies indicate that a combination of common but
lowly penetrant and rare but highly penetrant variants can
explain a large proportion of the susceptibility for ASD
[6,7]. Although single gene disorders with increased risk
for ASD, ASD-specific mutations and chromosomal copy
number variations are estimated to explain up to 20% of
the liability for the disorder [8], the majority of cases, as
well as the underlying biological pathomechanisms, re-
main elusive. This is in part due to the very wide differ-
ence of penetrance of each one of the three autistic core
impairments recognizable in autistic patients [9]. There-
fore, autism research now has a focus on the investigation
of common cellular pathophysiologies, within which indi-
vidual, patient specific malfunctions would generate a per-
sonalized autistic phenotype. So far, results obtained from
genetic, functional and biomarker screens have been gath-
ered to assemble the heterogeneous risk factors into path-
ways affected in ASD [10,11]. Among these are pathways
of energy metabolism, neurotransmitter signaling and/or
oxidative stress response and protein synthesis in the con-
text of synaptic plasticity [12-15]. These studies confirmed
that the functional impact of genetic variants is not only
determined by the known functional role of the gene
product, but also by its network context [16]. Thus, stud-
ies investigating putatively causative genetic variants in
cases of otherwise undefined genetic status may prove
beneficial for understanding malfunctions in cellular path-
ways altered in ASD [17].
We have previously characterized the genetics of two
rare X-linked, recessive amino acid substitutions in the
RPL10 gene (Ribosomal Protein of the Large Ribosomal
Subunit 10) co-segregating with ASD in three unrelated
German families [18,19]. At present, only a few other re-
ports on the genetics of human RPL10 are available.
Gong et al. did not identify any additional RPL10 muta-
tions when screening 141 patients, which could probably
be attributed to the low frequency of RPL10 mutations
[20]. At the level of mRNA expression, Gong et al. re-
ported no differential regulation of RPL10 in ASD [20].
This is supported by our showing that the RPL10 muta-
tions neither affect X-chromosomal inactivation nor alter
the overall mRNA expression levels of RPL10 [19]. How-
ever, a suggestive etiological role of RPL10 is emergingfrom genome-wide studies: for example, Piton et al. iden-
tified a novel exonic silent mutation C > T [A211A] [21] of
yet unknown pathological impact. Silent mutations have
been reported to influence translation kinetics and protein
folding [22,23]. While the pathophysiological role of the si-
lent RPL10 C > T [A211A] mutation is not known, we
note that the corresponding amino-acid position falls
within a RPL10 C-terminal sequence tract delineated by
the RPL10[L206M] and the RPL10[H213Q] mutations
identified in ASD patients described by us [18,19]. Piton et
al. did not identify non-synonymous mutations in RPL10
[21]. These results are underlined by the finding that the
functionality of RPL10 is readily compromised by single
amino-acid mutations affecting one of the many functions
of this translational regulator [24-26] rather than by
changes in copy number [27]. Again, this is in agreement
with both the rare occurrence of RPL10 single amino-acid
mutations in ASD specific screens and the results of two
genome-wide copy number variation (CNV) studies,
which reported de-novo copy number duplication span-
ning RPL10 in two independent male patients but not in
controls [14,28].
Collectively, our and other studies suggest that RPL10
dysfunction in ASD pathophysiology may be triggered
by either altered gene dosage or loss of function within
the cellular compartment of RPL10 activity. Indeed, we
and others have shown in the eukaryotic model system
yeast that selected mutations in rpl10 or altered gene-
dosage of rpl10 and other ribosomal proteins selectively
shift the mRNA expression profile to generate altered
expression levels of distinct protein sets [24,27]. At the
functional level, this is thought to be mediated by alter-
ing the role of Rpl10 during initiation of translation
[29,30] and mRNA recruitment and/or in the kinetics of
accommodating the incoming tRNAs during elongation
of protein synthesis [26]. Interestingly, we could show
that the rare RPL10 variants, L206M and H2013Q, re-
duce the cellular translational capacity in a yeast model,
that is, decrease of translating polysomes and increase in
translationally less active monosomes and free ribosomal
subunits [18]. It is known that wild-type yeast cells em-
ploy this strategy in response to a change in metabolic
conditions, either in response to a change in nutrient
availability [31] or in response to oxidative stress [32].
While reduction of translational capacity is associated
with reduction of global protein synthesis, it is also ac-
companied by increased expression of distinct stress re-
sponse proteins [32].
Studies in peripheral cells, such as lymphoblastoid cell
lines (LCL), have been successfully employed to study dys-
regulation of protein expression in ASD [33]. In a systematic
review Rossignol and Frye reported studies in LCLs that
monitored abnormalities in ASD within distinct pathways,
with the strongest evidence for immune dysregulation/
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making use of available LCLs we investigated the effect of
the human ASD-specific RPL10[H213Q] mutation [Gene-
bank NM_006013, c.639C >G] on cellular pathophysiology,
in particular on protein expression of LCLs, and performed
a comparative study employing an unrelated ASD patient
set.
The effect of the RPL10[H213Q] mutation on protein ex-
pression was analyzed by a comparative two-dimensional-
DIGE (difference gel electrophoresis) approach studying
RPL10[H213Q] mutation carriers, RPL10 wild-type relatives
and unrelated controls. Comparing RPL10[H213Q] induced
proteomic changes to protein patterns present in unrelated
ASD patients without any mutations in RPL10, we did not
find individually overlapping proteins, but rather identified a
common pattern among the differentially expressed proteins
related to the response to oxidative stress. Finally, in a proof
of principle study we aimed at testing the hypothesis that
rpl10 deficiency induces a protein expression pattern remin-
iscent of an oxidative stress response. When using a yeast
model system, we obtained evidence that indeed a gene-
dosage reduction of RPL10 generated a protein signature,
which was overlapping with the pattern observed in wild-
type cells subjected to oxidative stress.
This approach has allowed us to assess if and how the
proteomic network is altered by the autism-associated
RPL10[H213Q] mutation [Genebank: NM_006013, c.639C
>G] and to which degree the resulting proteomic signature
resembles alterations in protein expression present in the
general ASD population without RPL10 mutations. Finally
we are able to discuss our data in the context of substantial
literature reports on peripheral markers of ASD patho-
physiology [34] and references therein.
Methods
Selection of patients and controls
LCLs from RPL10[H213Q] mutation carrier families 277
and 440 [18,19] were available for the two male index
patients (hemizygous) and the mothers (heterozygous),
an unaffected carrier sister of family 440 (heterozygous)
and an unaffected wild-type half-brother of family 277.
Two randomly selected unrelated controls (male and
female) were chosen as wild-type controls for this RPL10
mutation study. For the study of ASD-specific protein pat-
terns LCLs from 10 male RPL10 wild-type ASD patients
(ASD setup) were matched for ethnicity (Caucasian) and
diagnosis (International Classification of Diseases 10th re-
vision (ICD-10): F84.0 with IQ >65) to the index patients
of families 277 and 440 [see Additional file 1: Table S1].
Ten cell lines from male uncharacterized Caucasian control
individuals with RPL10 wild-type were used as controls
(CTRL setup). RPL10 mutational status was confirmed by
direct sequencing. LCLs had been established as published
in Neitzel [35].The investigation conformed to the principles outlined in
the Declaration of Helsinki. All subjects or caregivers pro-
vided written informed consent for the participation in this
study and publication of this report which had been ap-
proved by the German local institutional ethics committees
in Frankfurt (Fachbereich Medizin der Johann Wolfgang
Goethe-Universität Frankfurt am Main, Ethik-Kommission)
and Heidelberg (Ethikkommission I der Medizinischen
Fakultät Heidelberg).
Growth conditions for lymphoblastoid cell lines
Viable cells (1 × 106) from a stationary phase culture
were inoculated into 5 ml RPMI medium supplied with
10% fetal bovine serum (FBS), 100 U/ml penicillin,
100 μg/ml streptomycin, 2 mM L-glutamine (all from
GIBCO®, Life Technologies, Paisley, UK). Volume was
doubled each time cultures reached a density of 1 × 106
cells/ml. Cells were harvested at a final density of 1 × 106
cells/ml in 40 ml by centrifugation at 700 × g for five
minutes and washed twice with PBS.
Yeast growth conditions
Yeast strains BY4743 (wild type (WT); genotype: MATa/
MATα his3Δ0/his3Δ0; leu2Δ/leu2Δ0; met15Δ0/MET15;
LYS2/lys2Δ0; ura3Δ0/ura3Δ0) and rpl10 deficient strain
(BY4743; genotype: MATa/MATα his3Δ 0/his3Δ0; leu2Δ /
leu2Δ0; met15Δ0/MET15; LYS2/lys2Δ0; ura3Δ0/ura3Δ0;
rpl10::kanMX4/RPL10) (all EUROSCARF, Frankfurt,
Germany) were grown in 100 ml synthetic complete media
with a starting concentration of OD600 = 0.1. Oxidative
stress was induced by applying 0.8 mM H2O2 after the cells
had reached an OD600 of 0.4. Cells were harvested at an
OD600 = 0.7 by centrifugation at 1,500 × g for five minutes
and washed twice with H2O.
Protein preparation
Protein preparation was performed at 4°C. LCL pellets were
resuspended in 750 μl DIGE lysis buffer (7 M urea, 2 M
thiourea, 30 mM Tris pH 8.5 and 4% 3-[(3-cholami-
dopropyl)dimethylammonio]-1-propanesulfonate (CHAPS),
all from Roth, Karlsruhe, Germany) and subjected to five
successive freeze and thaw cycles. Yeast cell pellets were re-
suspended in 1 ml DIGE lysis buffer for yeast (9 M urea, 4%
CHAPS, 30 mM Tris pH 8.8, all from Roth) and mechanic-
ally lysed using 0.45 mm acid-washed glass beads. The cyto-
solic protein fractions from LCLs or yeast cells were purified
by centrifugation at 13,000 × g for 20 minutes. The protein
concentration of the supernatant was measured using the
Protein Bradford Assay (Biorad, Munich, Germany).
Two-dimensional difference gel electrophoresis
Two-dimensional-DIGE experiments were performed as
previously published [36]. LCL and yeast protein ex-
tracts were processed the same way using the DIGE
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according to the manufacturer’s recommendation. All
individual samples were cyanine 5 (Cy5)-labelled and
compared to a Cy3-labelled equimolar mixture of all
samples (internal standard). Gels were scanned at a reso-
lution of 100 μm on the Typhoon 9200 Variable Mode
Imager (GE-Healthcare). DeCyder Software version 5.0
(GE-Healthcare) was used for spot detection and pri-
mary analyses; only spots with an area larger than 400
pixels and an intensity slope smaller than 2 were in-
cluded. At least 20 spots per gel were matched manually
and an additional 20 spots per gel were verified by man-
ual inspection after automated spot matching. On aver-
age, 1,200 spots per gel were successfully matched and
included in further calculations. The relative volume of
each individual spot was normalized against the respect-
ive internal standard. T-test on the log2 ratios (sample/
internal standard) comparing the two groups was per-
formed. For further statistical analyses ‘R’ software ver-
sion 2.15 was used.
Selection of spots of interest for identification
Spots of interest were defined based on two criteria:
first, candidate spots that were differentially regulated
and second, spots that had a variance which was differ-
ent between the two analyzed groups (this analysis was
only performed in the ASD versus CTRL setup).
To identify candidates relevant to the ASD etiology in-
cluding also the ones with small effects we decided to focus
on T-test P-values only including spots regulated below the
common threshold of 1.96 to 2 fold standard deviations.
After excluding the spots where the variance was simi-
lar for both (that is, the patient and control set), we fo-
cused on those spots where the variance was either
larger or smaller between the two biological groups. We
were also interested in minor changes and, thus, applied
F-test statistics at low threshold (F-test P-value 0.1).
In summary, protein spots were selected for tandem
mass spectroscopy (MS/MS) identification if: 1) the P-
value of the students T-test was below 0.05; or 2) if an
altered variance was detected (F-test P-value <0.10); and
3) if the protein spot was visible on a preparative two-
dimensional gel.
Protein identification and validation
For two-dimensional-preparative gels 500 μg of total
protein were used and Coomassie stained following pub-
lished protocols [37]. Picked protein spots were sent to
the Max Planck Institute, Department of Biochemistry,
Martinsried, Germany and identified by MS/MS.
Computational analysis
All statistical calculations were performed using DeCy-
der 5.0 or ‘R’ 2.15. Hierarchical cluster analysis wasperformed by applying the heatmap.2() function from the
R-package ‘limma’. Spots to be included in the cluster ana-
lysis were selected based on their P-values in the Bayes lin-
ear model predicting the biological groups using the R
function lmfit(). Three models were visualized including
candidates with P-values ≤ 0.05, ≤0.03 or ≤0.01. Best clus-
tering was observed when selecting spots with a Bayesian
model P-values ≤ 0.05 for ASD versus controls and ≤ 0.03
for RPL10[H213Q] mutation carriers versus non-carriers.
Network analysis was performed using Cytoscape ver-
sion 2.8.2 [38] with GeneMania plug-in version 3.2 [39].
Gene Ontology (GO)-term enrichment analysis was per-
formed using the BiNGO plug-in version 2.44 [40]. GO-
terms for biological processes (GOTERM_BP_FAT) for
each identified candidate (human or yeast) were re-
trieved from the Database for Annotation, Visualization
and Integrated Discovery (DAVID) [41].
The selection of the functional sub-networks was
based on key terms searched within the list of retrieved
GO-terms. Candidates were included in the network
named ‘Energy metabolism’ if they were associated with
a GO-term including the words ‘energy’ or ‘glycolysis’.
For ‘redox metabolism’ we applied the search terms ‘oxi-
dative stress’, ‘reduction’, ‘oxidation reduction’ or ‘perox-
ide’. The ‘Protein and mRNA metabolism’ network was
defined by the search terms ‘mRNA binding’, ‘mRNA
transport’, ‘mRNA degradation’, ‘protein metabolism/
catabolism/anabolism’, ‘protein folding’, ‘translation’,
‘protein localization’, ‘peptidase activity’, ‘ER’, ‘endoplas-
matic reticulum’ or ‘protein catabolism’. A list of the re-
trieved candidates and selected GO-terms is available in
Additional file 2: Table S7. We manually added RPL10 to
each list of genes if it was not a member by itself.
Selected candidates of the respective sub-networks were
analyzed and visualized based on co-expression using the
GeneMania plug-in mining expression data from the de-
fault 20 out of 161 databases for gene-expression available
within GeneMania. For details see [42].
Results
The impact of an ASD-associated RPL10 mutation on
differential protein expression was investigated compar-
ing LCLs of carriers of a RPL10[H213Q] mutation to
wild-type RPL10 carriers including two unrelated healthy
controls [see Additional file 1: Table S1 and Figure S1].
RPL10 mutant carriers were compared to RPL10 wild-
type carriers disregarding ASD diagnosis to identify pro-
tein expression patterns related to the mutation and not
to the ASD itself.
Two-dimensional difference gel electrophoresis
experiments
LCLs generally showed a large variance in protein expres-
sion, which can be attributed to the clonality effects
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within the set of all RPL10[H213Q] mutation carriers 62
significantly regulated candidate spots were observed [see
Additional file 3: Table S2] of which 7 were identified
using MS/MS (Table 1). Among the up-regulated candi-
dates we identified the lipid β-oxidation related enzyme
ECH1 (FC (fold-change) = 1.76, P-value = 0.0003) and the
translation elongation factor EEF1D (FC = 1.29, P-value =
0.0085). Furthermore, we observed differential expression
of two central glycolytic enzymes. We report a significant
down-regulation of three spots of different charge identi-
fied as TPI1 (triosephosphate isomerase, all spots with a
FC < −1.30 and P < .01) and a trend for GAPDH (glyceral-
dehyde 3-phosphate dehydrogenase, FC = −1.45, P-value =
0.0528). For TPI1 this suggests an alteration also on the
posttranslational level. Additionally, a mRNA regulatory
enzyme, HNRNPK (FC = −2.79, P-value = 0.0017), was
identified (Table 1, Additional file 3: Table S2).
Hierarchical cluster analysis using all detected protein
spots in RPL10[H213Q] carriers did not distinguish car-
riers from non-carriers. However, selecting spots that
were contributing to a Bayesian linear model (BLM) pre-
dicting mutation status with a significance of P-value
≤0.03 allowed correct clustering of individuals according
to mutation status. This criterion was fulfilled by 33
spots, among them TPI1, ECH1 and HNRNPK. GAPDH
was slightly above the threshold (BLM P-value = 0.0340)
and, thus, was excluded but should still be considered
as a biologically relevant target of differential protein
expression in a RPL10[H213Q] background. In addition,
using cluster analysis we were able to demonstrate that
the protein profile of RPL10[H213Q] carriers is distinct
from wild-type carriers, as the unaffected brother of
family 277 clearly maps to the cluster representing the
controls. Moreover, the protein signatures of the muta-
tion carriers themselves fall into two distinct groups,
representing the individual families’ genetic background
(Figure 1A). We conclude that BLM cluster analysis is
able to both separate carriers from non-carriers as well
as to report similarities within the carriers of the two
families.
To distinguish between RPL10[H213Q]-derived changes
and ASD-specific variations independent of the RPL10
mutation, we advanced to proteome analysis of LCLs de-
rived from 10 male patients, all with a comparable ASD
diagnosis and similar IQ and 10 unrelated randomly se-
lected male controls [see Additional file 1: Table S1 and
Figure S1]. Of the 1,215 detected protein spots 1,195
passed the quality criteria. We investigated protein pat-
terns with respect to change in protein expression level
(T-test P-value ≤0.05) and variance of protein expression
(F-test ≤0.1). Sixty-six candidates showed a significantly al-
tered expression level of which 17 spots were identified
using tandem MS/MS (Table 1), representing 15 differentproteins (PCBP1, ALDOC, ERP29, ECHS1, ATP5B, PSME2,
ACTB, TAGLN2, HNRNPA2B1, two isoforms, ATP5A1,
GAPDH, PGK1, two isoforms, HSPD1, PSMA1, GLUD1;
Table 1, Additional file 1: Figure S2, for full names see
Additional file 4: Table S4). Of the more than 200 pro-
tein spots that had a differential expression variance
we identified 10 proteins. Of these, four proteins had
also been identified as being differentially expressed
(ACTB, HNRNPA2B1, PSME2, PSMA1) and six add-
itional proteins exclusively showed an altered variance in
protein expression (ATP5H, EEF1D, HNRNPK, HNRPDL,
HSPA5, PRDX2, see also Table 1 and Additional file 5:
Table S3).
Clustering of individuals according to affected status was
not possible using all spots. The best hierarchical clustering
between ASD samples and controls was observed when
selecting spots that contributed to the underlying BLM
with a significance of P-value ≤0.05 (Figure 1B), suggesting
a specific set of proteins to be etiologically relevant. Twelve
of the 52 spots that fulfilled these criteria had already been
identified in the differentially regulated set mentioned
above. Again, a distinct protein signature emerged which is
differentiating cases and controls. However, we also note
that one of the control individuals has a protein profile
reminiscent of the ASD patient set (Figure 1B).
Candidate proteins (N = 21) collectively identified in the
ASD versus CTRL set mapped to etiopathologically rele-
vant pathways previously described in neurodevelopmental
disorders: energy metabolism (ALDOC, ATP5A1, ATP5B,
ATP5H, ECHS1, GAPDH, PGK1, GLUD1), mRNA and
protein metabolism (EEF1D, ERP29, HSPA5, HNRNPA2B1,
HNRPDL, HNRNPK, HSPD1, PCBP1, PSMA1, PSME2),
cytoskeleton (ACTB, TAGLN2) and redox scavenger
(PRDX2). Isoforms of two proteins, HNRNPA2B1 and
PGK1, were detected. For example, the glycolytic enzyme
PGK1 showed two spots down-regulated (FC < −1.11, and
P-values <0.05), suggesting again an alteration at the level
of post-translational modification.
Interestingly, none of the differentially expressed pro-
teins identified in the RPL10 family cohort was overlap-
ping with the differentially expressed proteins in the
general ASD cohort. However, an overlap within the
ASD cohort showing altered variance was observed. This
overlapping set included HNRNPK isoforms, EEF1D and
ECH1, which is the mitochondrial homolog to the per-
oxisomal ECHS1.
Validation of protein signatures
In an attempt to validate our proteome results with
other techniques, we used the investigated LCLs for RT-
PCR of candidate mRNAs [see Additional file 6: Table
S8] and Western blot analysis [see Additional file 7:
Table S9]. Of the five significantly regulated candidates
identified in RPL10[H213Q] versus RPL10-WT setup
Table 1 Proteins identified by tandem mass spectrometry following two-dimensional DIGE analysis
RPL10 vs Ctrl ASD vs CTRL MS/MS results
Namea Full name Spot No. FC T-test sig. FC T-test sig. F-test sig. Cov. Prot. Score Comment Network
ACTB Actin, beta 65 1.032 >0.1 −1.184 0.0127 0.0949 55% 216 Confirmed twice NA
ALDOC Aldolase C, fructose-bisphosphate 57 −1.375 0.0932 −1.277 0.0018 >0.1 44% 125 Mixture with PCBP1 Energy metabolism
ATP5A1 ATP synthase, H + transporting, mitochondrial
F1 complex, alpha subunit 1




ATP5B ATP synthase, H + transporting, mitochondrial
F1 complex, beta polypeptide
61 1.087 >0.1 1.151 0.0073 >0.1 16% 48 - Energy and redox
metabolism
ATP5H ATP synthase, H + transporting, mitochondrial
F0 complex, subunit d
77 1.036 >0.1 −1.013 >0.1 0.0896 67% 134 Confirmed twice Energy and redox
metabolism
ECH1 Enoyl Coenzyme A hydratase 1, peroxisomal 9 1.762 0.0003 −1.690 >0.1 >0.1 27% 46 - Energy metabolism
ECHS1 Enoyl Coenzyme A hydratase, short chain, 1,
mitochondrial
59 −1.016 >0.1 −1.405 0.004 >0.1 12% 43 Confirmed twice NA
EEF1D Eukaryotic translation elongation factor 1 delta 75 1.285 0.0085 −1.078 >0.1 0.0429 27% 71 - Protein and mRNA
metabolism
ENOA Alpha-enolase 20 −1.058 >0.1 −1.068 >0.1 >0.1 33% 81 Picked as potential
housekeeper
NA
ERP29 Endoplasmic reticulum protein 29 58 1.258 >0.1 2.287 0.0024 >0.1 1 Protb - Protein and mRNA
metabolism
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 18 −1.453 0.0528 −1.005 >0.1 >0.1 1 Protb - Energy and redox
metabolism
18c −1.061 >0.1 1.078 0.0294 >0.1 59% 191 -
GLUD1 Glutamate dehydrogenase 1 70 1.165 >0.1 −1.295 0.0289 >0.1 20% 78 Confirmed twice;
mixture with ATP5A1
Redox metabolism
HNRNP A2B1 Heterogeneous nuclear ribonucleoprotein A2/B1 71 −1.242 0.0796 1.173 0.0298 0.0391 58% 196 Confirmed twice Protein and mRNA
metabolism
18b 1.008 >0.1 1.100 0.0286 >0.1 45% 104 Confirmed twice
HNRNPK Heterogeneous nuclear ribonucleoprotein K 14 −2.792 0.0017 −1.209 0.0955 0.0003 13% 36 - Protein and mRNA
metabolism
HNRPDL Heterogeneous nuclear ribonucleoprotein D-like 80 −1.037 >0.1 1.073 >0.1 0.0323 19% 78 Confirmed twice Protein and mRNA
metabolism
HSPA5 Heat shock 70 kDa protein 5 (glucose-regulated
protein, 78 kDa)
21 −1.130 >0.1 1.004 >0.1 0.0589 21% 94 - Protein and mRNA
metabolism





19 −1.060 >0.1 1.025 >0.1 >0.1 30% 93 -




















Table 1 Proteins identified by tandem mass spectrometry following two-dimensional DIGE analysis (Continued)
PGK1 Phosphoglycerate kinase 1 72 −1.130 >0.1 −1.118 0.0299 >0.1 60% 176 Confirmed twice Energy metabolism
73 −1.513 >0.1 −1.117 0.0326 >0.1 45% 150 Confirmed twice
PRDX2 Peroxiredoxin 2 78 1.742 >0.1 −1.088 >0.1 0.0095 40% 147 Confirmed twice Redox metabolism
PSMA1 Proteasome (prosome, macropain) subunit,
alpha type, 1
51 −1.189 >0.1 −1.059 0.0483 0.0487 58% 132 Confirmed twice Protein and mRNA
metabolism
PSME2 Proteasome (prosome, macropain) activator
subunit 2 (PA28 beta)
63 1.115 >0.1 −1.226 0.0120 0.0526 38% 179 Confirmed twice Protein and mRNA
metabolism
TAGLN2 Transgelin 2 67 −1.026 >0.1 −1.190 0.0220 >0.1 1Protb - NA
TPI1 Triosephosphate isomerase 1 7 −1.350 0.0074 −1.043 >0.1 >0.1 NA Spot mappingc Energy and redox
metabolism
11 −1.430 0.0001 −1.038 >0.1 >0.1 34% 101 -
13 −1.436 0.0043 1.015 >0.1 >0.1 95% 192 -
aOfficial gene symbol; b1Prot: only peptides corresponding to the identified protein were identified; cSWISS-2DPAGE [44] Release 19.00*, Mapping reference gel: Acc: P60174: LYMPHOCYTE HUMAN. Proteins in bold
have been identified in the RPL10[H213Q] versus Controls (Ctrl) experiment, proteins in italics in the ASD versus CTRL setup. Cov, coverage; DIGE, difference gel electrophoresis; FC, fold change; MS/MS, tandem



















































































































































































































































































































































































































































































































Figure 1 (See legend on next page.)
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(See figure on previous page.)
Figure 1 Two-dimensional-DIGE results. (A) Hierarchical clustering of RPL10[H213Q] mutation carriers (MUT) and wild-type allele carriers (WT)
including spots with P-value ≤0.03 only. These 33 spots separated MUT from WT and, in addition, separately clustered families. Two distinct
protein clusters (A, B) are visible with cluster B being more affected in family 440. Asterisks mark samples from ASD patients. (B) Best hierarchical
clustering between ASD and controls (CTRL) was observed when selecting spots with P-value ≤0.05 (N = 52). Two distinct clusters are down- (A)
and up-regulated (B), respectively, in the ASD cohort. For better visualization missing values in A and B omitted during calculations are shown in
black. (C) In yeast, proteins differentially regulated under hydrogen peroxide (H2O2) induced oxidative stress overlap with a set of proteins
(marked in grey) differentially regulated in the rpl10 deficient yeast strain L10/ΔL10 (all P-values ≤0.05, comparison for both conditions are to
wild-type yeast). (D) Co-expression networks of identified candidates based on biological functions related to GO-terms. RPL10 was manually
spiked into each network and is co-regulated in every module. Gene-expression data are retrieved from the GeneMania database. For details on
methods and network construction see the Materials and Methods section. Symbols used in protein names in B and C: ‘&’ = a mixture of both
proteins was identified; ‘|’ =MS data were not able to clearly distinguish between named protein isoforms. ASD, autism spectrum disorders; DIGE,
difference gel electrophoresis; GO, Gene Ontology database; MS, mass spectroscopy.
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able to confirm increased protein expression for ECH1
(FC = 1.32; P-value = 0.0250 U-test), but no changes in
mRNA expression. Interestingly, we identified alterations
at the protein level in the RPL10[H213Q] mutation carriers
of candidate proteins identified in the ASD versus CTRL
setup, namely overall expression of ACTB, HNRPDL,
HSPD1 and PGK1 and specific isoforms of ALDOC and
ECHS1. These candidates were not significantly changed
in the two-dimensional DIGE experiment but the direction
of FC was comparable between the two setups.
For the ASD versus CTRL setup we were able to con-
firm reduction of ACTB (FC = −1.19, P-value = 0.041 U-
test) and observed a suggestive up-regulation for ERP29
(FC = 1.26, P-value = 0.096) at the protein level. At the
mRNA level we observed changes in the EEF1D and the
HNRNPK gene-expression. At the level of protein ex-
pression in the two-dimensional DIGE setup both can-
didates showed an altered variance but were not
differentially regulated. Our results suggest a predom-
inant regulation of the differentially expressed proteins
at the translational level. This is supported by a study
of Schwanhäusser et al. who quantified global mamma-
lian gene and protein expression and found that cellu-
lar abundance of proteins is predominantly controlled
at the level of translation [45].
Validation of protein signatures at functional levels
In search for validation of the candidate proteins on the
functional level we started to look for shared molecular
properties. The identification of a redox scavenger differing
in variance (PRDX2; F-test P-value = 0.0095) and sev-
eral differentially expressed mitochondrial enzymes (for ex-
ample, ATP5A1, ATP5B, ECHS1; all T-test P-values <0.03)
led us to the hypothesis of a redox-sensitive protein net-
work. Indeed, a literature search revealed that 22 out of
the total 25 candidates identified in this study (combining
RPL10[H213Q]-regulated and ASD-specific proteins) are
described as oxidative stress response proteins, or as regu-
lators of the levels of reactive oxygen species (ROS) (for
references see Additional file 1: Table S5).To investigate a possible link between alterations in
redox-sensitive proteins, energy metabolism, altered RPL10
function and change in protein expression pattern, we per-
formed a proof-of-principle study in yeast [see Additional
file 1: Figure S1]. First, we confirmed previous findings that
in response to oxidative stress, exemplified by H2O2
stress, yeast wild-type cells differentially express redox scav-
engers, redox-sensitive enzymes as well as glycolytic en-
zymes [46,47] (Figure 1C and Additional file 8: Table S6).
We observed regulation of yeast Tdh3 (one of the three
yeast GAPDH homologues), where two isoforms were
differentially expressed (FC = 1.34, P-value = 0.0027 and
FC = −1.07, P-value = 0.0118). Interestingly, proteome
analysis of the yeast rpl10 deficient strain under stand-
ard conditions and not subjected to oxidative stress
showed that 13 of 45 significantly (P-value ≤0.05) regu-
lated protein spots were up- or down-regulated in an
identical fashion as a subset of the overall set of H2O2
stress-regulated candidates in wild-type yeast cells [see
Additional file 8: Table S6, Figure 1C]. We were able to
identify in 9 of these 13 spots a total of 11 proteins: Asc1,
Cys4, Frd1, Rim1, a mixture of Rps5 and Cdc19, Ssb1 or
Ssb2, Tma19, Vma1, and Tma29 [see Additional file 4:
Table S4 and Additional file 8: Table S6, Figure 1C]. In
addition to the glycolytic enzyme Cdc19 (pyruvate kinase;
FC = −1.04, P-value = 0.0189), we also noted differential
regulation of a Tdh3 isoform, however with a suggestive
significance only (FC = −1.03, P-value = 0.0777, Additional
file 8: Table S6).
The overlap in glycolytic proteins in the RPL10[H213Q]
mutant carriers, the ASD patient set, the oxidatively
stressed yeast cells and the yeast cells with rpl10 deficiency
suggested a gene ontology association study. Indeed, a first
investigation on biological processes revealed enrichment
for energy metabolism, protein and mRNA metabolism,
and redox metabolism [see Additional file 2: Table S7 and
Additional file 1: Figure S2]. Subsequently, based on
their GO-terms, we selected those candidates of related
function – protein and mRNA metabolism, energy me-
tabolism and redox metabolism – and performed a
gene co-expression network analysis based on available
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see Methods and Additional file 2: Table S7). For both
yeast and human mRNA expression data, we observed
that the individual networks of the selected candidates
built ensembles that are co-regulated at mRNA levels
with RPL10 (Figure 1D). In addition, the tight co-
regulation at mRNA levels of the RPL10[H213Q] and the
ASD candidate proteins strengthens the reported functional
overlap between the molecular phenotypes generated by the
RPL10 mutation and the ASD cohort, respectively.
Discussion
An estimated 1 out of 110 individuals in the US is cur-
rently affected by ASD [1]. For decades up until now ASD
has been clinically defined by behavioral observations fol-
lowing standard manuals. In spite of tremendous effort,
the etiology of ASD is still unclear and large consortia
have obtained genetic evidence that the majority of ASD
cases do not result from simple gene or chromosomal dis-
order. A meta-analysis of research trends in ASD con-
ducted by Rossignol and Frye indicates that in addition to
dysfunctions of the CNS thought to be causative for the
cognitive and behavioral features of ASD, pathophysiol-
ogies that transcend specific CNS function accompany
most ASD cases [49]. These authors combined reports ob-
tained in neurocognitive areas with focus on CNS mal-
function (neuroimaging, neuropathology, theory of mind
and genetics) with reports on the study of pathophysio-
logical processes that could more directly result in cellular
dysfunctions and the subsequent development of psychi-
atric disorders, such as ASD. In particular, there are well
documented differences in ASD patients compared to
controls in immune response, especially that of the gastro-
intestinal tract [50], in oxidative stress response/redox
regulation and general detoxification [51], as well as in en-
ergy metabolism and associated mitochondrial function
[52]. One common theme of all pathophysiological param-
eters reported in this meta-study is their relatively small,
albeit significant, deviation from the respective level in
typically developed controls. While different systemic ab-
normalities may accompany most ASD cases, they must
be small to allow for organismal viability. In sum, this
study suggests that ASD, rather than being a purely CNS
disorder, displays a wide range of systemic abnormalities
making the study of peripheral cells and systemic fluids an
attractive target to investigate the etiology of ASD.
The results of our study mirror in several ways the docu-
mentations of Rossignol and Frye [34]. First, we report that
an ASD-associated RPL10[H213Q] mutation alters protein
expression patterns similar but not identical to the one ob-
served in an unrelated ASD cohort without this mutation.
This suggests a common downstream pathophysiology
resulting from different unidentified upstream genetic vari-
ants. Second, the RPL10[H213Q] expression signaturedifferentiating carriers from non-carriers, is modified by the
genetic background of the carriers within families, as ob-
served in cluster analysis. We hypothesize that distinct dif-
ferent protein expression levels in individuals may define
distinct pathophysiological phenotypes. Furthermore, while
RPL10[H213Q] heterozygous carriers, all women, and
RPL10[H213Q] hemizygous carriers, all ASD cases, share
common motifs in altered protein expression, the contribu-
tion of the remaining wild-type RPL10 [19] to the establish-
ment of a healthy or subclinical phenotype of the female
carriers has not been studied here. Thus, it remains to be
tested if the protein signatures identified here ultimately
correlate with severity of ASD as reported for mitochon-
drial biomarkers (for an extensive meta-review compare
Rossignol and Frye [49]).
Third, the protein signatures observed in the RPL10
[H213Q] mutant cohort and in the unrelated ASD co-
hort are characterized by both having different expres-
sion levels and containing different redox-sensitive
members of identical pathways. This is in agreement
with observations made by Rossignol and Frye [34],
namely that depending on the study cohort, overlap is
observed in same pathophysiologies.
To assess the phenomenon of oxidative stress and
redox control in the context of ASD pathophysiology it
is important to recall that endogenous oxidative stress
results from an excess of ROS which no longer can be
reduced to non-pathological levels by anti-oxidant scav-
enger and repair mechanisms. Ultimately, all excess ROS
are generated by malfunctions in energy metabolism,
primarily fueled by glycolysis in the cytoplasm and the
tricarboxylic acid (TCA) cycle and oxidative phosphoryl-
ation (OXPHOS) in mitochondria. The successive break-
down of carbon fuels during glycolysis and the TCA cycle
supplies electrons to the electron transport chain for mito-
chondrial OXPHOS to produce ATP and H2O. During
this process leakage of electrons results in the formation
of ROS, the superoxide radical (O2–), hydrogen peroxide
(H2O2) and the hydroxyl radical (OH). If increasing
amounts of ROS escape detoxification, excess oxidative
power attacks lipids, proteins and DNA (reviewed in [53]).
Lipid peroxidation is detrimental to the function of recep-
tors and ion channels in all cellular membranes and, thus,
also to the balance of membrane potential in the neuron
[54]. Loss of control over membrane potential, in turn, has
been reported to affect receptors’ function [55] and may
thus lead to altered signal transduction between pre- and
post-synaptic membranes. Protein oxidation leads to loss
of enzyme function and/or loss of structural integrity [56].
Oxidation of DNA is a major source of somatic mutations
[57]. Each of these pathologies is harmful to all cells and
has been shown to have a severe negative impact on neural
cells, in particular in the context of inflammation and syn-
aptic function [54,58]. On the level of protein expression,
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Figure 2 ASD mutation-induced redox-sensitive protein signatures compromise core synaptic functions in autism. (A) The ribosome
recruits mRNAs, encoding proteins for specific pathways (black, green, blue mRNAs). Subsets of mRNAs are under the control of the translational
regulator RPL10 (orange), which itself is controlled by upstream regulators (grey). This forms a protein signature characteristic for example for
mRNA and protein metabolism (black), redox-metabolism (green) and energy metabolism (blue). (B) In the presence of (mis)functional RPL10
variants (for example, RPL10[H213Q]) or other ASD variants (red crosses) regulating RPL10 the protein signatures are selectively shifted (red
rectangles) resulting in alterations (change in number of the framed protein spots) of pathway-specific redox-sensitive proteins as observed here.
The altered protein signature thus indicates a response to oxidative stress elicited by the ASD mutation(s). (C) In peripheral tissues, for example, a
lymphoblast, deficiencies in RPL10 or upstream regulators thereof alter the redox-sensitive signature in a way which in the presence of moderate
ROS (reactive oxygen species) production (small red bolt) is still able to balance cellular stress response. In particular, altered expression of the
glycolytic enzyme GAPDH (blue) may be employed for redox buffering by rerouting glycolysis into the PPP (pentose phosphate pathway). This
will increase reductive power to balance oxidative power caused by ROS. (D) Under conditions of high oxygen metabolism (large red bolt) as
present in neural cells, redox buffering will still support basal synaptic functions, but may no longer be able to prevent oxidative damage of lipids
and proteins required for cellular fine-tuning (undulations) of synaptic functions and plasticity (purple, double headed arrow). We hypothesize that
the effect of different ASD-mutation induced protein signatures would drive individual autistic phenotypes with differential failure to secure
correct executing of synaptic plasticity. Question marks indicate unknown individual steps. ASD, autism spectrum disorders.
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alter mRNA translation in model systems [32,59].
Altered translation has been until now one of the best
documented cellular processes executing correct synap-
tic plasticity by modulating density and composition
of synaptic proteins, the loss of which is one of the hall-
mark pathologies in ASD brain tissue [60]. Our obser-
vation that altered availability of the translational
regulator RPL10 generates a cellular redox-sensitive
stress response signature in the yeast model, suggests
that a mutation in human RPL10 could trigger a similar
phenomenon in neural cells. This is supported by ourobservation of a redox-sensitive protein signature in
LCLs of RPL10[H213Q] patients.
How then might an ASD-mutation modulate oxidative
stress in the periphery and the CNS of ASD patients?
First, a mutation in a translational regulator, such as the
ribosomal protein RPL10, might result in unscheduled
or increased recruitment of redox-sensitive proteins that
are a mimic of the translational response driven by other,
more upstream ASD genetic variations (for example, pro-
vided by different genetic backgrounds). Basically, in all
these cases this scenario would supply the cell with a simi-
lar compromised redox microenvironment as observed in
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other or even most ASD cases remains to be established.
Second, several affected genes in our study encode en-
zymes that were reported to produce or eliminate ROS
and thus, when mutated lead to loss of control of ROS
production associated with impaired gene expression [51].
Third, any enzyme directly active in energy metabolism,
when mutated, would fulfill the criteria for an autism can-
didate gene, as it ultimately would favor imbalance in
mitochondrial ROS production. This is underscored by a
series of enzymes of glycolysis, the TCA cycle and
OXPHOS found to be affected in neuropsychiatric dis-
eases [61,62]. GAPDH and TPI, identified in this study to
be differentially regulated in ASD, have been reported to
be differentially expressed in brains of schizophrenia pa-
tients [63]. The close neighborhood of the RPL10 protein
to both proteins in the energy metabolism co-expression
network may thus underscore the etiological relevance of
RPL10 in neurodevelopmental disorders. Finally, a protein
identified as dysfunctional in ASD may be directly sensitive
to cellular redox status, either by oxidative stress induced
alterations in posttranslational modifications [64,65] or by
shifting the equilibrium of redox-sensitive disulphide bonds
in regulatory proteins [66]. The former proposal is sup-
ported by the observation of differential expression of post-
translationally altered proteins in our study, and the latter
one by redox-sensitive disulphide bonds reported for ASD
candidate proteins [66,67].
For a discussion of putative functional roles of individ-
ual proteins identified with the redox-sensitive proteins
signature in the etiology of ASD we will focus on the
ASD candidate protein RPL10, which is co-expressed
with candidates in all three GO-term enriched networks
identified in both human and yeast studies (Figure 1D). A
second such protein is GAPDH/TDH3 which was highly
connected within the co-expression networks of energy
metabolism (human and yeast) and redox response (hu-
man and yeast) as well as mRNA and protein expression
(yeast only, as human GAPDH is so far not GO-term an-
notated with translation or mRNA regulation).
The glycolytic enzyme GAPDH is a redox-sensitive key
enzyme of glycolysis and together with its immediate glyco-
lytic neighbor TPI1 (Figure 1D) has previously been re-
ported to be differentially regulated in schizophrenia [63].
This functional interaction of human RPL10 mutations
with glycolytic enzymes is confirming previous findings
from yeast studies [24,25]. GAPDH and other glycolytic en-
zymes are receiving increasing interest as regulatory pro-
teins in differentiation and disease [68]. It has been shown
that isoforms of GAPDH and downstream glycolytic en-
zymes are expressed in different metabolic stages in yeast
[69] as well as in cellular differentiation in mammalian cells
[70]. These studies propose that posttranslational modifica-
tions of GAPDH and other glycolytic enzymes, sometargeted by oxidative modification, make these glycolytic
enzymes to platforms within the successive stages of energy
metabolism, which can be used to switch between high and
low levels of energy metabolism [69]. For example, several
studies have shown, that reduction of GAPDH function
reroutes the glycolytic flow to the pentose phosphate path-
way, used to generate NADPH, which serves as the redu-
cing power to restore glutathione (GSH) levels in the GSH/
GSSH redox couple, the major intracellular antioxidant/
detoxification species [71]. Alterations in GAPDH func-
tion, induced by mutation, altered expression level
or change in posttranslational modification, may thus
affect energy metabolism and redox status, which is of
particular importance in high energy consuming cells
like neurons.
Ribosomal protein RPL10 is also of specific interest to
further studies on the etiology of ASD. So far, translational
regulators described in more detail as mediating dysfunc-
tional translation in ASD are FMRP [72] and eukaryotic
initiation factor 4E, eIF4E [73]. FMRP is a translational
repressor binding to and, thereby, preventing protein syn-
thesis of synaptic mRNAs. Mutated FMRP leads to un-
scheduled protein synthesis at the synapse, resulting in
compromised synaptic plasticity [74]. Also, mutationally
altered eIF4E leads to hyperconnectivity of neural circuits
due to increased synaptic protein synthesis. EIF4E is a key
component of the eukaryotic translation initiation ma-
chinery, which when over expressed leads to increased ex-
pression of neuroligins, which are postsynaptic proteins
that are causally linked to ASD [73]. RPL10 is a compo-
nent of the translating ribosome and different modifica-
tions of RPL10 may alter different ribosome functions, for
example mutations in RPL10 have been described that
alter translation initiation [30] or protein expression levels
[24]. At present, we do not know if there are modifications
of RPL10 resulting from upstream regulators of transla-
tion, for example upstream regulators of synaptic protein
expression and/or oxidative stress response. If so, it would
be interesting to learn whether they are known ASD can-
didate proteins.
In sum, our results on differential redox-sensitive pro-
tein expression patterns in patients with RPL10[H213Q]
mutations and unrelated RPL10 wild-type ASD patients,
in particular in the context of alterations in energy
metabolism and protein translation, have led us to for-
mulate the following hypothesis (Figure 2). The altered
redox-sensitive protein signature, as observed in per-
ipheral cells derived from our patient sets, mirrors a
cellular response to oxidative stress. We suppose that
this signature is largely compatible with normal cellu-
lar function in peripheral tissues under conditions of
moderate ROS levels. However, the brain is the organ
with the highest oxygen consumption and metabolism
[53] and, thus, we propose that in the presence of high
Chiocchetti et al. Molecular Autism 2014, 5:10 Page 13 of 15
http://www.molecularautism.com/content/5/1/10oxygen turnover in neural cells, the altered redox-
sensitive protein signatures may fail to buffer oxidative
stress in energy metabolism, redox metabolism and
protein metabolism. To arrive at a molecular under-
standing of the role of an individual, RPL10-regulated
and differentially expressed redox-sensitive protein,
GAPDH may serve as an example (Figure 2). GAPDH
is a key glycolytic enzyme and major player in rerout-
ing reductive power to balance increased oxidative
stress. In the process of adapting to different levels of
cellular oxidative stress, GAPDH may tolerate only a
distinct range of change in expression level. While the
altered expression level of GAPDH observed in lym-
phoblastoid cells may be compatible with effective
redox control in this cell type, it may fail to provide the
required response to the high oxygen metabolism
present in a neuron. If this insufficiency in the pres-
ence of high oxygen stress either results from a loss of
regulatory flexibility and/or inadequate network func-
tion as a consequence of the differentially expressed
state, remains to be established.
Consequently, we propose that ASD-mutation induced
altered redox-sensitive protein signatures fail to balance
the high oxidative stress in the neuron. The resulting ex-
cessive oxidative damage may compromise correct func-
tioning of synaptic proteins and membrane potential to
execute synaptic plasticity.
Conclusions
Here, we show for the first time in a patient-specific cell
line model for ASD that ASD patients, either with
defined or with undefined mutations at the level of pro-
tein expression, display modulated expression of redox-
sensitive components in those cellular pathways that
execute synaptic plasticity in the brain: energy meta-
bolism, redox metabolism and protein metabolism. In-
dividual differences in these expression patterns may
contribute to the phenotypic continuum observed in
the wide spectrum of ASD patients.
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